JAMA Psychiatry

Evidence review: Maternal mental conditions drive climbing death rate in U.S.

Retrieved on: 
Wednesday, February 21, 2024
Mental health, Woman, PNP, Suicide, Infection, Prenatal development, Hospital, Public health, Bleeding, MPA, Fatality, Maternal death, Mental, DSM-IV codes, Pregnancy, Communication, Death, Internal bleeding, Risk, Health, JAMA Psychiatry, FACOG, University, Infant, Disease, Mother, White, Health policy, Maternal health, Child, Mortality, Drug overdose, George Washington University, Research, Medicine, Depression

“The contribution of mental health conditions to the maternal morbidity and mortality crisis that we have in America is not widely recognized,” said Katherine L. Wisner, M.D.

Key Points: 
  • “The contribution of mental health conditions to the maternal morbidity and mortality crisis that we have in America is not widely recognized,” said Katherine L. Wisner, M.D.
  • , associate chief of Perinatal Mental Health and member of the Center for Prenatal, Neonatal & Maternal Health Research at Children’s National.
  • Overdose and other maternal mental health conditions are taking the lives of more than twice as many women as postpartum hemorrhage, the second leading cause of maternal death.
  • Mental health conditions such as suicide or opioid overdose are to blame for nearly 23% of maternal deaths in America, according to reports from three dozen Maternal Morbidity and Mortality Review Committees, which are state-based organizations that review each maternal death within a year of pregnancy.

Study results of psilocybin treatment in bipolar II depression published in JAMA Psychiatry

Retrieved on: 
Wednesday, December 6, 2023
Psychiatry, JAMA Psychiatry, Headache, MD, Therapy, MADRS, Mental health, Annual general meeting, Bipolar II disorder, American College, Safety, Patient, CMPS

Results from the investigator-initiated open-label study were first presented at the Annual Meeting of the American College of Neuropsychopharmacology in 2022.

Key Points: 
  • Results from the investigator-initiated open-label study were first presented at the Annual Meeting of the American College of Neuropsychopharmacology in 2022.
  • The study, which was conducted by Dr Scott Aaronson at Sheppard Pratt, Baltimore, and funded by Compass, investigated the safety and efficacy of a single 25mg dose of COMP360 psilocybin treatment in participants with treatment-resistant bipolar II.
  • The primary endpoint was change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week 3.
  • “In what we believe to be the first study of its kind, we saw a significant number of patients experience relief from their bipolar II depression symptoms after a single 25mg dose of COMP360 psilocybin treatment.

First-Ever Psilocybin Clinical Trial for Treatment of Bipolar II Depression Conducted at Sheppard Pratt Reveals Promising Results

Retrieved on: 
Wednesday, December 6, 2023
Psilocybin, Hypomania, Depression, Safety, Research, Argyreia nervosa, Therapy, Treatment, Post-traumatic stress disorder, Ageing, Bipolar II disorder, Clinical trial, Bipolar I disorder, Psychotherapy, Patient, Tic disorder, Psychopharmacology, Psychiatry, Suicide, Trial of the century, JAMA Psychiatry, Mania, Hearing, Psychosis, Pharmaceutical industry

BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- JAMA Psychiatry recently published a first-of-its-kind clinical trial conducted at Sheppard Pratt studying the efficacy and safety of a single dose of synthetic psilocybin accompanied by psychotherapy in treating individuals with treatment-resistant bipolar type II disorder (bipolar II).

Key Points: 
  • BALTIMORE, Dec. 6, 2023 /PRNewswire/ -- JAMA Psychiatry recently published a first-of-its-kind clinical trial conducted at Sheppard Pratt studying the efficacy and safety of a single dose of synthetic psilocybin accompanied by psychotherapy in treating individuals with treatment-resistant bipolar type II disorder (bipolar II).
  • The study revealed promising results with 80% of participants meeting remission criteria 12 weeks after treatment.
  • The results of this study suggest the efficacy and safety of psilocybin in treatment of bipolar II depression, but cannot be extrapolated to the study of psilocybin to treat bipolar I disorder.
  • Sheppard Pratt's Center of Excellence for Psilocybin Research and Treatment is currently conducting clinical trials on psilocybin with psychotherapy for the treatment of anorexia, treatment-resistant depression and chronic suicidal ideation.

Decriminalizing Drug Possession Not Linked to Higher Overdose Death Rates in Oregon or Washington

Retrieved on: 
Wednesday, September 27, 2023
Nuffield Department of Population Health, Doctor of Public Health, University, Network, Methamphetamine, MPP, NYU, Health, Ground substance, New York University Grossman School of Medicine, United States drug overdose death rates and totals over time, Research, National Vital Statistics System, Heroin, Person, Imprisonment, University of Michigan School for Environment and Sustainability, CDC, Public health, University of Michigan School of Public Health, Cocaine, Population health, JD, Korea Disease Control and Prevention Agency, Public health law, Supreme court, Psychiatry, NYU Langone Health, Drug, 2020 Oregon Ballot Measure 110, MPH, Fentanyl, JAMA Psychiatry, Pharmaceutical industry, Doctor of Philosophy, Policy, Medicine

The research team's goal was to investigate whether fully or partially decriminalizing drug possession changed rates of overdose deaths in either state in the first year after the policy change.

Key Points: 
  • The research team's goal was to investigate whether fully or partially decriminalizing drug possession changed rates of overdose deaths in either state in the first year after the policy change.
  • Critics, meanwhile, argue that decriminalizing the possession of small amounts of drugs might increase drug use and subsequent fatal overdose.
  • "These two studies show that drug decriminalization measures in Oregon and Washington reduced arrests and did not increase overdose deaths.
  • The researchers then constructed a synthetic control group made up of 13 states that had similar rates of overdose to Oregon and 18 states that had similar rates to overdose in Washington pre-decriminalization.

Together, the All-in-One AI Health Assistant, Improves Care for Aging Americans With Voice-Based Mental Health Detection Feature

Retrieved on: 
Wednesday, August 30, 2023
VoIP, Software, Mobile, Wireless, General Health, Telemedicine, Virtual Medicine, Mental Health, Apps, Applications, Technology, Artificial Intelligence, Health Technology, Practice Management, Health, Clifford Whittingham Beers, Blood pressure, Kaiser, JAMA, Obesity, Depression, Face, Google Play, Anxiety, Ageing, Kaiser Family Foundation, Android, Multimedia, MIT, App Store (iOS/iPadOS), American Medical Association, Journal, DSM-IV codes, Patient, Risk, Frustration, Apple, Conditional sentence, Heart rate, MIT Lincoln Laboratory, JAMA Psychiatry, Caregiver, PharmacoEconomics, Nursing, Mobile phone, Medical device

Together , the leading AI-based health assistant, today unveiled its latest groundbreaking feature: Mental Vitals, an innovative mental health detection tool designed to screen for symptoms of depression and anxiety through voice analysis.

Key Points: 
  • Together , the leading AI-based health assistant, today unveiled its latest groundbreaking feature: Mental Vitals, an innovative mental health detection tool designed to screen for symptoms of depression and anxiety through voice analysis.
  • "Our mission with Together is to unify every aspect of health care, from vitals monitoring to mental health detection, into one intuitive platform," said Dr. Renee Dua, founder and chief product officer of Together.
  • According to a Mental Health America 2023 survey report , 54% of adults with a mental illness did not receive treatment.
  • By combining mental health detection, vital measurement, and routine health management, Together can be uniquely effective as an AI-driven patient-centric care coordination and whole-person health platform.

CAMH study confirms ongoing brain inflammation associated with long COVID

Retrieved on: 
Thursday, June 1, 2023
Inflammation, Depression, Anxiety, CAMH, COVID-19, Hope, PET, Brain, Research, COVID, Amnesia, Parkinson's disease, Patient, TSPO, Psychiatry, Motivation, JAMA Psychiatry, Encephalitis, Memory, Fatigue, Pharmaceutical industry, Medical imaging, Medical device

TORONTO, June 1, 2023 /CNW/ - A new CAMH study published in the journal JAMA Psychiatry found elevated levels of inflammation in the brain of patients who report persistent symptoms of long COVID.

Key Points: 
  • TORONTO, June 1, 2023 /CNW/ - A new CAMH study published in the journal JAMA Psychiatry found elevated levels of inflammation in the brain of patients who report persistent symptoms of long COVID.
  • "We already knew that there is brain inflammation in people who died in the midst of a severe, active COVID-19 infection.
  • "Inflammation in the brain was suspected of being the critical step in causing neurological and psychiatric symptoms of long COVID so confirming this is vital to develop treatments for people experiencing symptoms."
  • Most participants also experienced a variety of other lingering symptoms associated with long COVID, including extreme fatigue and problems with concentration and memory often referred to as 'brain fog'.

New Research Finds Dramatic Increase in Illegal Ketamine Seized by Authorities, Sparking Concern About Potential Dangers of Rising Recreational Use

Retrieved on: 
Wednesday, May 24, 2023
Linda, Columbia University, Seizure, Nuffield Department of Population Health, Yale University, Telehealth, Depression, University, GHB, COVID-19, Fear, NYU, Ground substance, New York University Grossman School of Medicine, Research, Heroin, Bangladesh Technical Education Board, Government, NYU Langone Health, Dissociative, Cocaine, National Institute on Drug Abuse, Patient, Risk, Population health, Ketamine, Drug, MPH, Chronic pain, Fentanyl, JAMA Psychiatry, MDMA, Dietary supplement, Pharmaceutical industry, Health, Doctor of Philosophy

"Unlike illegal ketamine years ago, most illegally obtained ketamine today is not pharmaceutical grade and is sold in powder form which may increase the risk that it contains other drugs such as fentanyl."

Key Points: 
  • "Unlike illegal ketamine years ago, most illegally obtained ketamine today is not pharmaceutical grade and is sold in powder form which may increase the risk that it contains other drugs such as fentanyl."
  • He also warns that media and medical promotion of prescription ketamine in recent years is fueling black-market use and availability.
  • NDEWS continues to monitor the use and effects of ketamine and many novel drugs to alert the public about alarming trends in a timely manner.
  • The content of this research is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Clinicians Identify Buprenorphine “Spiking” In JAMA Psychiatry Study Supported by Millennium Health Researchers

Retrieved on: 
Wednesday, March 22, 2023
Pharmaceutical, Science, Health, Research, Spiking, Doctor of Pharmacy, Buprenorphine, University, Urine, UDT, Department of Medicine – University of Pamplona, Opioid use disorder, OUD, Doctor of Philosophy, Pain, University of Colorado School of Medicine, MHS, Public health, Patient, Immunoassay, Johns Hopkins Bloomberg School of Public Health, JAMA Psychiatry, Pharmaceutical industry, MD

Spiking a urine sample represents intentional addition of buprenorphine tablet or residue directly into the urine to mimic adherence with prescribed buprenorphine.

Key Points: 
  • Spiking a urine sample represents intentional addition of buprenorphine tablet or residue directly into the urine to mimic adherence with prescribed buprenorphine.
  • Detecting spiking allows clinicians to adjust or intensify the treatment plan.”
    “At Millennium Health we have been tracking the enormity of the drug use crisis.
  • This study suggests that spiking is an important patient safety issue, and it is not uncommon,” said study co-author Eric Dawson, PharmD, VP of Clinical Affairs, Millennium Health.
  • Immunoassay based, point-of-care tests cannot detect spiking because they are generally incapable of quantitative analysis and differentiating buprenorphine from norbuprenorphine.”

New Study from The Fenway Institute Undercuts the Rapid Onset Gender Dysphoria Hypothesis

Retrieved on: 
Monday, March 20, 2023
National Center for Transgender Equality, Risk, Gender identity, University, Suicidal ideation, Transgender, Massachusetts General Hospital Psychiatry Academy, Parent, Policy, Disclosure, Gender variance, Health, Economist, JAMA Surgery, Public policy, ROGD, Impact of the COVID-19 pandemic on neurological, psychological and other mental health outcomes, History, Health policy, Bentham Science Publishers, Puberty, Journal, Assistant professor, Publication, Standards of Care for the Health of Transgender and Gender Diverse People, Adolescent health, Division, The New York Times, Manuscript, Psychiatry, Adolescence, Realization, Transgender youth, Turban, Faculty, TGD, Healthcare and the LGBT community, JAMA Psychiatry, Female, Fenway Health, Toy, Nursing, Science, Pediatrics

BOSTON, March 20, 2023 /PRNewswire-PRWeb/ -- A study published in the Journal of Adolescent Health found that a substantial proportion of transgender and gender diverse (TGD) adults realized that their gender identity is different from their sex assigned at birth during adolescence or later. It also found that TGD people typically waited many years before sharing this realization with another person. The study adds important new knowledge to clinical and popular understanding of the timing of TGD people's awareness, understanding, and sharing of their gender identity. It also undercuts a core component of the "rapid onset gender dysphoria" (ROGD) hypothesis, which posits that TGD identities realized in adolescence are transient and will not continue into adulthood.

Key Points: 
  • The study adds important new knowledge to clinical and popular understanding of the timing of TGD people's awareness, understanding, and sharing of their gender identity.
  • It also undercuts a core component of the "rapid onset gender dysphoria" (ROGD) hypothesis, which posits that TGD identities realized in adolescence are transient and will not continue into adulthood.
  • Participants were also asked how old they were when they first shared their gender identity with another person.
  • Published in Pediatrics, that study provided evidence undercutting the "social contagion" component of the ROGD hypothesis.

Helping patients with addiction tackle their health needs

Retrieved on: 
Thursday, November 10, 2022
Division, Health, Doctor of Philosophy, Partnership, MSW, Kaiser Permanente, JAMA Network Open, Mental health, Mortality, JAMA Psychiatry, Disorder, District, Patient, Cunningham, Curriculum, Physician, Doctor of Public Health, Health promotion, Doctor of Psychology, Addiction medicine, MD, Health education, Caregiver, Medicine, Pharmaceutical industry, Research

OAKLAND, Calif., Nov. 10, 2022 /PRNewswire/ -- An intervention that teaches patients in addiction treatment how to better connect with their primary care medical team on both mental and physical health concerns resulted in long-term benefits over 5 years, including more primary care use and fewer substance-related emergency department visits, Kaiser Permanente researchers have found.

Key Points: 
  • "I have lost patients not from their drug addiction, but from health conditions that they neglected, perhaps because of their drug addiction," she said.
  • Iturralde said it was gratifying that the study found long-term benefits from helping patients learn to manage their health and engage with the health care system.
  • We are recognized as one of America's leading health care providers and not-for-profit health plans.
  • Kaiser Permanente is dedicated to care innovations, clinical research, health education, and the support of community health.